

A study on non-synonymous mutational patterns in structural proteins of SARS-CoV-2

Jayanta Kumar Das^{a,*}, Swarup Roy^{b,*},

^a*Department of Pediatrics, Johns Hopkins University School of Medicine, Maryland, USA*

^b*Network Reconstruction & Analysis (NetRA) Lab, Department of Computer Applications, Sikkim University, Gangtok, India*

Abstract

SARS-CoV-2 is mutating and creating divergent variants across the world. An in-depth investigation of the amino acid substitution in the genomic signature of SARS-CoV-2 proteins is highly essential for understanding its host adaptation and infection biology. A total of 9587 SARS-CoV-2 structural protein sequences collected from 49 different countries are used to characterize protein-wise variants, substitution pattern (type and location), and major substitution changes. The majority of the substitutions are distinct, occurred mostly in a particular location, and leads to a change in amino acid's biochemical properties. In terms of mutational changes, Envelope (E) and Membrane (M) proteins are relatively stable than Nucleocapsid (N) and Spike (S) proteins. Several co-occurrence substitutions are observed, particularly in S and N proteins. Substitution specific to active sub-domains reveals that Heptapeptide Repeat, Fusion peptides, Transmembrane in S protein, and N-terminal and C-terminal domains in N protein are remarkably mutated, and also found few deleterious mutations in these domains.

Keywords: Mutation, Amino acid substitution, Structural proteins, Biochemical properties, Functional sub-domains.

1. Introduction

The outbreak of novel Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV-2), causing the disease COVID-19. With the passage of time a good number of variants are reported so far across the globe. Though the rate of mutation in SARS-CoV-2 observed to be relatively low, even then the variants of SARS-CoV-2 are differed by a number of mutations in their genome. Mutations in the nucleotide sequence can prevent binding PCR primers to target sequences [1]. Different biological properties such as pathogenicity, tissue tropism or host range can happen diversely in closely related variants too [2, 3]. Couple of studies reveal that mutation can triggers enzyme motion in dihydrofolate reductase [4], impact on three-dimensional structure, stability and redox potential [5], hydrophobic effect [6], functional diversity in the proteins. The same may be observed even in the structurally similar proteins [7, 8, 9].

The genetic diversity in SARS-CoV-2 may impact on molecular functionality of the protein [10]. Mutation and sequence variant analysis is crucial for understanding the disease pathogenesis and structural changes in the SARS-CoV-2 proteins, which ultimately helps in designing more stable small molecules that may binds viral proteins.

Mutation is the key factor that trigger a virus to switch hosts [11]. SARS-CoV-2 genome shows different degree of similarity with other coronaviruses. SARS-CoV-2 genome is highly

*Corresponding Author

Email addresses: jdask4@jhmi.edu (Jayanta Kumar Das), sroy01@cus.ac.in (Swarup Roy)

19 similar with SARS-related coronaviruses ¹ derived from Pangolin [12] or Bat [13, 14]. A minor
20 dissimilarity [15] might leads to the variation in functionality of SARS-CoV-2 protein with
21 other class of coronaviruses. Scientists observing variants in novel coronavirus strains due to
22 mutation, insertion or deletion reported from different geographical regions [16, 17, 18].

23 At least 26 protein-coding genes are available in each SARS-CoV-2 genome that encodes
24 mainly three classes of proteins, such as nonstructural (Nsp1-Nsp16), structural (Spike glycoprotein-
25 S, Envelope-E, Membrane-M and Nucleocapsid - N), and several accessory protein chains
26 [19, 20]. The two-third of the complete genome is at the 5' site that encoding the nonstruc-
27 tural proteins, and one-third are at the 3' side which encodes structural and accessory proteins
28 [19]. SARS-CoV-2 proteins play a diverse functional role. Mutations in structural proteins can
29 alter various functionality of the virus, more importantly protein from this class initiate host
30 jumping mechanism. For example, the envelope protein promotes viral assembly and release
31 [21]. The Spike protein responsible for the occurrence of spikes on the viral surface that binds
32 to host receptors [21] and it is mainly responsible for receptor recognition, cell attachment, and
33 fusion during viral infection [22, 23, 24]. The Nucleocapsid protein capable of self-association
34 through a C-terminal [25, 26] and it activates the expression of cyclooxygenase-2 [27]. The
35 roles of Membrane protein include promoting membrane fusion, regulating viral replication,
36 packing genomic RNA into viral particles, interaction with other proteins [28, 29, 30]. Both
37 the spike and nucleocapsid proteins are in the main target for antibody detection [31]. Many
38 of the sequence variability features of structural proteins are still unknown and need to be
39 investigated thoroughly.

40 Studies on three severe class of coronaviruses have shown that hydrophobic interaction
41 in receptor binding motif for SARS-CoV and SARS-CoV-2 could allow the spike protein for
42 zoonotic transmission [32]. Further, insertion of an extra charged amino acid residue in SARS-
43 CoV-2 receptor-binding domain, creates a larger hydrophobic surface that underlies the higher
44 binding affinity of SARS-CoV-2 to ACE2 compared to SARS-COV [32] and that might allow
45 more flexibility for zoonotic transmission. In comparison to Bat and Pangolin coronavirus,
46 SARS-CoV-2 sequence seems to possess specific modifications and characteristics than other
47 SARS-CoV viruses [33]. For instance, in case of homologous coronavirus proteins, positively
48 charged amino acid (Arg69) replaces negatively and neutrally charged Glu or Gln residues.
49 Moreover, a deletion specific to SARS-CoV-2 proteins flanks this position. In a different stud-
50 ies have highlighted the impact of the non-synonymous substitutions, that change biochemical
51 properties of amino acids, are highly crucial for protein stability, binding with receptors, sub-
52 strate specificity, affinity of amino acid change [34, 35, 36, 37, 38, 39]. Therefore, amino acid
53 insertion, deletion and even substitution playing significant role towards attaching with recep-
54 tor proteins that could impact on the binding affinity of SARS-CoV-2 protein. Several other
55 studies on SARS-CoV-2 have shown that a mutation can trigger protein structure alteration,
56 dynamics and function while binding with human receptor protein (ACE2) [40, 41, 42, 43].
57 Therefore, these studies are important to understand the clinical presentation and spread of
58 the disease, and also useful for antiviral drug design [44, 45].

59 In this study, we focus on sequence variability of worldwide SARS-CoV-2 genome, particu-
60 larly four structural proteins. For each protein, we identify unique variants. Then we identify
61 and localize the amino acid substitution in each variant. Substitutions are then quantified and
62 categorised according to their type and physico-chemical properties of amino acids. We then
63 report country-specific unique variant and substitution type in each structural protein.

¹<https://www.ecohealthalliance.org/2020/01/>

64 2. Materials and methods

65 To the best of our knowledge no prior research analyse different SARS-CoV-2 strains col-
66 lected from 49 different countries across the global to understand the worldwide sequence
67 variation due to mutation. In this section we report the sequence used and various exploratory
68 analysis performed on the sequences.

69 2.1. Sequence dataset

70 We collect around 9,587 SARS-CoV-2 complete genomic (nucleotide) sequences of length
71 $\approx 28kb$ from NCBI database reported till 15th July 2020. We exclude sequences with undeter-
72 mined character present within the sequence for our analysis, and obtain 9058, 8954, 8271 and
73 7009 number of sequences for Spike (S), Envelope (E), Membrane (M), Nucleocapsid (N) pro-
74 tein, respectively. Collected sequences are then grouped based on similarity to isolate unique
75 variants for further analysis.

76 2.2. Multiple sequence alignment

77 The unique list of sequences (one representative from each group) are aligned using mul-
78 tiple sequence aligner (MSA) to observe possible insertion or deletion in amino acid residues.
79 We select first reported sequence from Wuhan city of China (2019-nCoV/USA-WA1/2020,
80 Accession number: MN985325/NC_045512), E-protein (Accession number: QHO60596.1);
81 M-protein (Accession number: QHO60597.1); N-protein (Accession number: QHO60601.1);
82 S-protein (Accession number: QHO60594.1) as a reference sequence. We use MEGAX [46]
83 for MSA. We observe few sequences with indels in Spike and Nucleocapsid proteins, which we
84 separately analyze as reported in *Supplementary-A (Figure S1 and S2)*, and all the remaining
85 sequences are considered for subsequent analysis.

86 2.3. Amino acid substitution identification

87 The amino acid substitution (or non-synonymous mutation) is a common phenomenon
88 in virus genome and the rate of substitution is mainly depends on the protein's expression
89 level, functional category, metabolic costs, hydrophobicity and electrostatic, physicochemical
90 properties, annotated active or binding site [47, 48, 49, 39].

91 To understand and observe any pattern during amino acid substitutions in the collected
92 strains, we compare each and every aligned sequences with the reference sequence and report
93 position-wise substitutions. In our study, we try to identify all possible substitutions for twenty
94 (20) amino acids ($20 \times 20 - 20 = 380$) without considering synonymous substitutions and
95 categorizing them based on similar substitution patterns.

96 2.4. Investigating the change in biochemical properties

97 Amino acid substitutions due to non-synonymous mutation may change the biochemical
98 properties of the target proteins. We categorize observed amino acid substitutions based on
99 the change in the chemical properties. Here, we consider two kinds of broad groupings based on
100 the biochemical properties of amino acid. One is eight chemical sub-groups based on side-chain
101 structure [50], and the other is three Hydropathy classes of amino acids [51]. The sub-groups
102 in each category are as follows:

- 103 • **Side-Chain based classes:** According to this grouping 20 amino acids are clustered as
104 Acidic (D, E), Basic (R, H, K), Aromatic (F, W, Y), Aliphatic (A, G, I, L, V), Cyclic
105 (P), Sulfur (C, M), Hydroxyl (S, T), and Amide (N, Q).
- 106 • **Hydropathy based classes:** Three such groups include Hydrophobic (A, C, I, L, M,
107 F, W, V), Neutral (G, H, P, S, T, Y) and Hydrophilic (R, N, D, Q, E, K).

108 Our major goal is to highlight what kind of biochemical properties are majorly changed
109 (quantitatively) due to substitution.

110 2.5. Functional domains of SARS-CoV-2 structural proteins

111 The SARS-CoV-2 structural protein (particularly S and N) encompasses several sub-domains
112 responsible for a specific functional activities. Few of them are:

- 113 • **Transmembrane (TM)** is a stretches of amino acids responsible for viral entry [52, 53].
- 114 • **Heptapeptide Repeat 1-2 (HR1, HR2)** are responsible for virus fusion [54].
- 115 • **Receptor-Binding domain (RBD)** is mainly responsible for binding of the virus to
116 the receptor protein [53].
- 117 • **N-terminal (NTD) and C-terminal domain (CTD)** are two main RNA binding
118 domains in SARS-CoVN protein [26]. Both of them function as a receptor-binding entity.
119 CTD recognizes the receptor and NTD engages the receptor [55].
- 120 • **Fusion peptides (FP)** are created fusing using two or more genes playing different
121 functional roles. The FP play an important role in fusion of viral envelope with host
122 cellular membranes [56].

123 The typical length of SARS-CoV-2 spike (S) protein domain is 1273 amino acids. Primarily
124 it consists of three units: a) a signal peptide (amino acids 1–13) located at the N-terminus; b)
125 the S1 subunit (14–685 residues), which is consisting of N-terminal domain (14–305 residues)
126 and a receptor-binding domain (RBD, 319–541 residues); and c) the S2 subunit (686–1273
127 residues), which is consisting of the fusion peptide (FP) (788–806 residues), heptapeptide
128 repeat sequence 1 (HR1) (912–984 residues), HR2 (1163–1213 residues), Transmembrane (TM)
129 domain (1213–1237 residues), and cytoplasm domain (1237–1273 residues) [57].

130 Usually SARS-CoV-2 nucleocapsid (N) protein domain consists of 419 amino acids. SARS-
131 CoV-2 N protein contains two distinct RNA-binding domains: the N-terminal domain (NTD,
132 44-179 residues) and the C-terminal domain (CTD, 247-363 residues) [58]. These two domains
133 are linked by a poorly structured linkage region (LKR), and N-tail and C-tail domain at the
134 beginning and end of the protein domain.

135 Identification of substitutions, particularly in functional domains, might help understand
136 the virulence power of SARS-CoV-2 . Therefore, we try to highlight the substitutions in
137 different functional domains in the next section.

138 2.6. Software tools and programming

139 For predicting whether a mutation is deleterious or neutral, we use software tool *PROVEAN*².
140 *PROVEAN* (Protein Variation Effect Analyzer), a web server software tool, is used to predict
141 any non-synonymous amino acid substitution or indel impacts on the biological function of a
142 protein [59]. We utilize a recently developed mutation simulation tool [60] which generates
143 fine-grained simulated random mutations in any genome. We use Python scripting 3.7 for
144 quantitative analysis.

145 3. Results and Discussion

146 3.1. Grouping identical variants

147 At first, similar sequences are grouped for each structural protein. We observe 24, 51, 258,
148 364 number of groups (distinct variants) for E, M, N and S protein, respectively (Figure 1(a)).
149 The distinct variants are represented as v_1, v_2, \dots, v_k (k is the number of distinct variants

²<http://provean.jcvi.org/index.php>

150 observed in each protein category). If we consider the group size for different proteins, we
 151 observe that more than 95% of the samples from E and M proteins sharing two groups and
 152 85% samples from N and S proteins distributed in two groups (Figure 1(c)). We observe a
 153 maximum variation in S protein followed by N, M and E proteins. It further reveals interesting
 154 fact that in terms of mutational changes E and M proteins are relatively stable than N and S
 155 proteins. A country-wise variants and its count (sample frequency) for each structural protein
 156 is listed in *Supplementary-A (Table S1)*.

157 While studying the number of substitutions (or substituted positions) occurs in each variant,
 158 interestingly we observe maximum of seven (07) substituted positions. We represent number of
 159 substituted positions by numbering, for example, one substituted positions by 1p, two substi-
 160 tuted positions by 2p, and so on. Out of which single substitution occurring most commonly,
 161 whereas seven number of substitutions are rarely occurring in different candidate proteins (Fig-
 162 ure 1(b)). In case of E and M protein, we observe only single amino acid substitution position
 163 in each variant. For N protein, number of substitutions varies from 1p to 4p numbers, whereas
 164 for S protein, count varies from 1p to 7p.




Figure 1: The quantification of observed variant and non-synonymous substitutions positions in each SARS-CoV-2 structural protein. (a) collected sample with observed distinct variants; (b) Variant frequency with number of substituted positions; (c) Percentage of sample frequency for the top two variant class (v_1 and v_2).

165 3.2. Substitution patterns and locations

166 In this section, we first try to investigate the substitution patterns in comparison to our
 167 reference sequence. All possible substitutions (source to target amino acid) are shown in a 2D
 168 matrix representation in Figure 2. In general, there could be $20 \times 20 - 20 = 380$ possible
 169 unique non synonymous substitutions considering twenty amino acids. The value in each cell of
 170 the matrix depicts the count for a particular substitution from a source (row) to target amino
 171 acid (column) occurs in different locations in different proteins, we consider.

172 Irrespective of variant and position of substitutions, we can observe from the Figure 3, a
 173 total 316, 217, 50, 23 number of amino acid substitutions in S, N, M, E protein, respectively.
 174 To understand how much random the location of substitutions in different proteins, we observe
 175 a variable number of substitution locations such as 261 ($\approx 21\%$ of sequence length) for S, 167
 176 ($\approx 40\%$ of sequence length) for N, 45 ($\approx 20\%$ of sequence length) for M, and 19 ($\approx 25\%$
 177 of sequence length) for E protein. Interesting, these findings show that mutation location in the
 178 N protein is most random and difficult to localize or predict its site of alternation. M protein
 179 relatively most stable in such scenario.




Figure 2: The figure shows amino acid substitution by position count. The amino acid substitution type is shown by a 2D matrix relation. In figure, a substitution type, say $P > Q$, indicates left amino acid P (y-axis, left) (source) to substitution right right amino acid Q (x-axis, top) (target), and the cell value in the matrix indicates observed number of substitution positions for that particular substitution type (from Figure 4).

180 It is evident from our analysis that a total 91 types of substitutions are observed in S
 181 proteins. Similarly, for N, M and E proteins total 74, 33, and 19 types of substitutions are
 182 observed. A position-wise substitutions in each proteins is shown in Figure 4. A number of
 183 substitutions in different proteins showing multiple target amino acids in the same location.
 184 For example, in case of N proteins, four target amino acids (K, M, S and G) as substitutions
 185 are found in position 203 distributed across 36 variants (*Supplementary-B*).

186 The top few substitutions (based on sample frequency) are observed common in the majority
 187 of the countries in different SARS-CoV-2 structural proteins (Figure 5), which are $P > L(71)$ in
 188 E protein; $T > M(175)$ in M protein; $R > K(203)$, $G > R(204)$ and $S > L(194)$ in N protein;
 189 $D > G(614)$ and $L > F(54)$ in S protein. Several substitutions are observed, mostly specific
 190 to in different countries, with sample frequency 3 or more as depicted in the Figure 5. The
 191 complete list of substitutions patterns observed in different countries (with sample frequency
 192 ≥ 1) can be seen from *Supplementary-C*.

193 3.3. Trend of substitutions by change in amino acids

194 Amino acid substitution changes the linear organization of peptide bond, and hence some
 195 changes can lead to abnormal functionality and disrupting its structure. So, we focus on amino
 196 acid substitution by different types of amino acid change looking into substitutions in different
 197 positions. Majority of substitutions are observed distinct and occurring mostly in particular




Figure 3: The figure shows observed total number of substitution irrespective of positions and variants, total substitution in all positions, observed substitutions by positions, and unique substitution count for each structural protein (S, N, M, E).

198 position (Figure 2). We observe maximum substitutions for $A > V$, which occurs in 19 different
 199 positions followed by $A > S$ (17 different position) and $L > F$ (13 different positions) in S
 200 protein. In case of N protein, we observe maximum substitution for $T > I$, which occurs in 15
 201 different positions followed by $P > S$ (12 different position) and $P > L$, $A > S$ and $D > Y$
 202 (11 different positions). In case of M protein, we observe maximum substitution for $A > S$
 203 (15 different positions), and we do not observe more than two substitutions in any particular
 204 position in case of E protein.

205 Towards understanding amino acid change by substitutions type, we calculate the percent-
 206 age by observing all substitutions occurring in all positions (discussed above). There are two
 207 categories of substitution we consider, one to many and many to one fixing a particular source
 208 or target amino acid. For both the categories, the total substitution count, the number of
 209 distinct substitution type (from Figure 2), and their percentages for each category of proteins
 210 are calculated. The top 5 substitutions are reported in Table 1. Majority of the amino acid
 211 changes from L to other in both the envelope (E) protein ($\approx 17\%$, 3 distinct types) and mem-
 212 brane (M) protein ($\approx 20\%$, 4 distinct types). In case of nucleocapsid (N) protein, substitutions
 213 occur for S to other ($\approx 13\%$, 10 distinct types). For spike (S) protein, we observe A to other
 214 change is the maximum ($\approx 14\%$, 5 distinct types). However, maximum distinct substitution
 215 are observed in S to others (10 distinct types).

216 We also observe several co-occurrence substitutions in Spike (S) and Nucleocapsid (N)
 217 proteins (Table 2). For example, dominant substitution $D > G$ (614) in S protein is co-occurred
 218 with $L > F$ (54) in 53 samples and $L > F$ (5) in 39 samples. Similarly, in N protein, dominant
 219 substitution $R > K$ (203) is co-occurred with $G > R$ (204) in 766 samples.

220 3.4. Trend of substitutions by changing chemical properties of amino acids

221 A non-synonymous substitution that alters the amino acid, in tern alter the biochemical
 222 properties of the amino acid. In this section, we categorise the substitution type by observing
 223 their chemical properties of amino acids. We consider two kinds of biochemical properties, eight
 224 chemical properties of amino acids and three Hydropathy class of amino acid as discussed in
 225 Section 2.4.

226 In the case of side-chain structure change (using eight chemical properties of amino acids),
 227 most of the substitutions change its chemical properties. We see 77 out of 91 ($\approx 85\%$), 61
 228 out of 74 ($\approx 82\%$), 24 out of 33 ($\approx 73\%$), 15 out of 19 ($\approx 83\%$) of substitutions in S, N,

S								N								M		E	
Pos.	Type	Pos.	Type	Pos.	Type	Pos.	Type	Pos.	Type	Pos.	Type	Pos.	Type	Pos.	Type	Pos.	Type		
2	F>L	176	L>F/H	393	T>P	732	T>A	1122	V>L	3	D>Y	163	Q>K/R	284	G>E	2	A>S/Y	5	V>I
5	L>F	177	M>I	403	R>K	740	M>I	1124	G>Y	4	M>D	165	T>I	289	Q>H/H/L	3	D>G/Y	7	E>Q
7	L>Y	178	D>M	408	R>I	745	D>G	1129	V>A	6	P>L/T	166	T>I	292	I>T	4	S>F	8	E>D/K
8	L>Y	180	E>K	441	L>I	750	S>I/R	1136	T>I	9	Q>H	167	L>F	294	Q>L	10	V>A	9	T>I
9	P>L	185	M>K	457	R>K	751	M>D	1141	L>F	11	M>S	168	P>Q	297	D>Y	11	E>G	19	L>F
12	S>F/C	188	M>D/K	471	E>Q	752	L>R	1143	P>L	13	P>L/T	169	K>R	298	V>H	13	L>F	20	F>L
13	S>I	190	R>K	476	G>S	765	R>L/S	1153	D>Y	14	R>H	180	S>I/G/T	300	H>Y	15	K>R	26	F>L
14	Q>H	197	I>Y	477	S>M	768	T>I	1162	P>L/S	18	G>C/Y	183	S>Y	301	W>C	23	V>L	36	A>Y
17	M>K	200	Y>S	483	V>A/F	769	G>Y	1163	D>G	19	G>R	185	R>C/L	302	P>S	25	G>Y	37	L>R
18	L>F	203	D>M	485	G>R	772	V>I	1168	D>H	20	P>L	186	S>F	309	P>L	29	L>F	39	L>M
21	R>I	211	M>Y	494	S>P	778	T>I	1176	V>F	22	D>G/Y/M	187	S>L	311	A>S	33	C>F	41	A>S/Y
22	T>I/M/A	213	V>L	501	N>Y	783	A>S	1181	K>R	23	S>T	188	S>P/L	319	R>L	34	L>F	43	C>S
25	P>S/L	214	R>L	519	H>Q	789	Y>D	1187	M>K/Y	24	T>I	190	S>I	320	I>V	38	A>S	55	S>F
26	P>L	216	L>F	520	A>S	791	T>I	1191	K>M	25	G>F	191	R>H/L	321	G>D	46	L>F	62	V>F
27	A>S/Y	218	Q>L	522	A>S/Y	795	K>Q	1192	M>T	30	G>A	192	M>S	322	M>Y/H	48	I>T	68	S>F/C
28	Y>H/M	220	F>L	529	K>E	797	F>C	1195	E>Q	32	R>L	193	S>I/M	325	T>I/R	62	L>S	71	P>L/S
29	T>I	221	S>L	547	T>I	808	D>G	1201	Q>K	33	S>I	194	S>L	326	P>L/S	63	A>T	72	D>Y
32	F>L	222	A>P/Y	553	T>I/M	809	P>S	1203	L>F	34	G>I/W	195	R>I/K	327	S>L	64	C>F	73	L>F
38	Y>C	239	Q>R	554	E>D	812	P>S/T	1205	K>M	35	A>S/T/Y	196	M>S	329	T>M	69	A>S/Y	75	V>F
43	H>Y	240	T>I	558	K>R	818	I>S/Y	1219	G>C/Y	36	R>L	197	S>L	330	W>L	70	V>F/H		
50	S>L	242	L>F	561	P>L	827	T>I	1228	V>L	37	S>L	198	T>I	334	T>I	75	W>L		
54	L>F	245	H>R	570	A>V/S	829	A>T	1230	V>L	40	R>C/L	199	P>S/T	337	I>F	85	A>S/D		
67	A>S/Y	247	S>R	572	T>I	832	G>C	1237	M>I/T	43	Q>R	200	G>S	340	D>M/G	87	L>F		
69	H>Y	248	Y>H	574	D>Y	836	Q>L/P	1243	C>F	46	P>S	202	S>M	342	K>M	89	G>S		
70	Y>F	252	G>S	580	Q>H	838	G>D/S	1246	G>S	60	G>R	203	R>K/M/S/G	344	P>S	98	A>S		
71	S>F	253	D>G	583	E>D	839	D>M	1247	C>F	62	E>Y	204	G>R	348	D>Y/H	107	R>L		
74	M>K	254	S>F	594	G>S	845	A>S/D/Y	1248	C>F	63	D>M	205	T>I	361	K>I	109	M>I		
75	G>Y	255	S>F	611	L>F	846	A>Y	1250	C>F/Y	67	P>T/S	207	P>L/S	362	T>I	123	P>L		
76	T>I	258	W>L	613	Q>H	854	K>R	1254	C>F	70	Q>H	208	A>G	364	P>L/R	124	L>F		
78	R>M	261	G>R	614	D>G	859	T>I	1259	D>H	79	S>T	209	R>H/K/T	365	P>L/S	125	H>Y		
80	D>Y	262	A>T/S	615	V>F	879	A>S/Y	1260	D>M/H	81	D>Y	210	M>I	368	P>S	129	L>Y		
86	F>S	265	Y>C	621	P>S	884	S>F	1263	P>L	83	Q>R	211	A>S	371	D>Y	132	P>S		
88	D>Y/A	267	V>L	622	V>A/F/H	892	A>S/Y	1264	V>L	89	R>I	212	G>C	372	K>R	138	L>I		
90	Y>F	271	Q>R	623	A>S	922	L>F			90	A>S	213	M>Y	373	K>M	142	A>Y		
95	T>I	273	R>S/M	626	A>Y	924	A>Y			92	R>S	215	G>C/Y	376	A>S	145	L>F		
96	E>G/D	275	F>Y	631	P>S	929	S>I			95	R>L	218	A>Y	377	D>G/Y	146	R>H		
97	K>T	276	L>I	640	S>F/A	930	A>Y			97	G>S	220	A>T	378	E>A	155	H>Y		
98	S>F	279	Y>M	647	A>S	931	I>Y			105	S>M	228	M>Y	379	T>I	158	R>L		
102	R>I	288	A>T	653	A>Y	936	D>Y			119	A>V/S	229	Q>H	380	Q>H	170	V>L		
111	D>M	298	E>G/K	655	H>Y	939	S>F/Y			120	G>R	230	L>F	381	A>Y	175	T>M		
118	L>F	300	K>M	672	A>Y	940	S>F			122	P>L	232	S>R/H/T	383	P>S/L	190	D>M		
127	V>F	302	T>L	675	Q>H/R/K	981	L>F			125	A>T	234	M>I	384	Q>H	199	Y>C		
132	E>D	307	T>I	676	T>I/S	1002	Q>E			128	D>Y/H	235	S>F/P	385	R>I	208	T>I		
138	D>H	308	V>L	677	Q>H/R	1020	A>V/S			134	A>Y	236	G>C/Y	386	Q>H/K	209	D>Y		
142	G>Y	309	E>Q	681	P>L	1063	L>F			135	T>I	237	K>T	391	T>I	214	S>I		
145	Y>H	314	Q>K/L/R	682	R>Q/W	1065	V>L			139	L>F	238	G>C	393	T>I				
146	H>Y	315	T>I	684	A>T/S/Y	1078	A>S/Y			140	M>T	243	G>C	397	A>S				
148	M>S/Y	321	Q>L	688	A>Y	1079	P>S			142	P>S	246	V>A	398	A>S/Y				
151	S>G/H	323	T>I	690	Q>H	1083	H>Q			144	D>Y/H	247	T>I/A	399	D>E/H				
152	W>L/R	330	P>S	691	S>F	1085	G>R			145	H>Y	249	K>R	401	D>Y				
153	M>I	345	T>S	698	S>L	1091	R>L			146	I>F	250	S>F	402	D>Y				
155	S>I	348	A>S/T	701	A>Y	1101	H>Y			151	P>L/S	252	A>S	413	S>I				
156	E>D	354	M>K	704	S>L	1103	F>L			152	A>S	255	S>F/A	416	S>L				
157	F>L	367	V>F	706	A>S	1104	V>L			154	M>Y	260	Q>L/E						
158	R>S	379	C>F	708	S>F	1109	F>L			155	A>Y	270	V>L						
162	S>I	382	V>E/L	724	T>A	1118	D>Y			156	A>S	271	T>I						
173	Q>H	384	P>L	731	M>I	1120	T>I			157	I>T	282	T>I						

Figure 4: The figure shows observed amino acid substitution by position and type, which are obtained from across all the variants and shown by each structural protein shaded at the top (S, N, M, E).

229 M, and E protein, respectively, that transit to different chemical groups. In case of E and M
 230 proteins, majority of the substitutions leads change in chemical properties from Aromatic to
 231 Aliphatic, Aliphatic to Hydroxyl-containing for M protein, Hydroxyl-containing to Aliphatic
 232 for N protein, Aliphatic to Aromatic and Hydroxyl-containing for S protein (Figure 6(a)).

233 In case of, more than 50% substitutions (except E protein), we observe a change of one
 234 Hydropathy class to another. We observe 50 out of 91 ($\approx 55\%$), 46 out of 74 ($\approx 62\%$),
 235 17 out of 33 ($\approx 52\%$), 8 out of 18 ($\approx 44\%$) of substitutions in S, N, M, and E protein,
 236 respectively, that changes the Hydropathy class. The significant change in Hydropathy classes
 237 from Hydrophilic to Hydrophobic (S, N and E protein), and Hydrophobic to Hydrophilic (M
 238 protein) (Figure 6(b)).


Table 1: The table shows top 5 substitution type and associative quantitative information for two categories. For a substitution $X > Y$, in the the first category, X is fixed and Y can be any amino acid, and in the second category, X is any amino acid and Y is a fixed.

X > any					Any > Y				
Protein	AA	Count	Distinct	Percentage	Protein	AA	Count	Distinct	Percentage
E	L	4	3	17.39	E	F	6	3	26.09
E	E	3	3	13.04	E	L	3	2	13.04
E	V	3	2	13.04	E	S	3	3	13.04
E	A	3	2	13.04	E	I	2	2	8.70
E	S	3	2	13.04	E	V	2	1	8.70
M	L	10	4	20.00	M	F	11	4	22.00
M	A	10	4	20.00	M	S	8	4	16.00
M	V	5	4	10.00	M	I	6	5	12.00
M	D	4	3	8.00	M	L	5	4	10.00
M	R	3	2	6.00	M	V	5	3	10.00
N	S	30	10	13.82	N	L	31	7	14.29
N	P	29	5	13.36	N	S	30	5	13.82
N	R	23	9	10.60	N	I	29	5	13.36
N	D	22	5	10.14	N	Y	17	4	7.83
N	A	22	4	10.14	N	T	16	7	7.37
S	A	43	5	13.61	S	L	39	8	12.34
S	S	29	10	9.18	S	S	39	9	12.34
S	T	28	6	8.86	S	F	38	4	12.03
S	V	24	5	7.59	S	I	38	6	12.03
S	Q	21	6	6.65	S	V	29	4	9.18

Table 2: The dominant substitutions that are co-occurred with other substitutions (with sample frequency 5 or more) in Spike(S) and Nucleocapsid (N) protein.

Protein	Substitution (a)	Co-occurred substitution with (a)	Sample frequency
S	D>G(614)	L>F(54)	53
		L>F(5)	39
		S>N(477)	37
		H>Y(146)	21
		S>L(221)	17
		P>L(681)	16
		D>G(253)	14
		N>Y(501)	13
		Q>H(677)	13
		T>I(572)	11
		E>D(583)	11
		Q>H(14)	8
		R>M(78)	8
		V>L(308)	8
		R>K(403)	8
		A>D(845)	7
		P>L(1263)	7
		F>L(220)	6
		D>H(138)	6
		H>Y(49)	6
		S>F(939)	6
T>I(859)	6		
N	R>K(203)	G>R(204)	766
		G>R(204);I>T(292)	16
		G>R(204);Q>H(229)	10
		G>R(204);T>I(205)	5
		A>G(208)	6
		T>I(393)	6
		E>V(62)	6
		S>L(194)	6
P>L(13)	28		
S>L(197)	28		

246 Although receptor binding domain in S protein is equally important for viral entry to host [53],
 247 we observe comparatively few substitutions ($\approx 12\%$ locations) in this domain. We then predict
 248 whether the mutations/substitutions in functional domains are deleterious or neutral. We find



(a) Change percentage by eight chemical properties of amino acids by substitution. (b) Change percentage by Hydrophathy classes of amino acids by substitution.

Figure 6: The trends of substitution type (percentage) shown by percentage for two categories of amino acid biochemical property. The circle in the figure indicates the proportion of changes percentage from one group to another.

eleven (11) deleterious mutations in functional domain of S protein (*Supplementary-A (Table S2)*), which are distributed in RBD domain (*C379F, V382E*); FP domain (*F797C*); HR1 domain (*A924V, S929I, A930V, D936Y, S939F, S939Y, S940F*); HR2 domain (*L1203F*). From our study we may assume that SARS-CoV-2 favours mutations in HR1 and FP to become more virulent by making the mechanism of host cell membrane fusion and entry to host cell more improved.

In case of N protein, we observe substitutions in both the NTD and CTD domains ($\approx 30\%$ locations). We observe few substitutions in NTD and CTD domain are related to charged amino acids. This may leads to issues in RNA packaging in the virus [61]. Although the molecular mechanism of SARS-CoV-2 N protein is yet to explore thoroughly [62]. There are total of twenty (25) deleterious mutations are observed, 13 in CTD domain and 12 in NTD domain (*Supplementary-A (Table S3)*).

3.6. Comparison of real vs. simulated mutations

Various simulation tools are developed assuming certain probabilistic distributions followed during genetic mutations. It may be interesting to verify whether mutations in SARS-CoV-2 follow similar distributions or not. We use very recently developed mutation simulation tool [60] which generates fine-grained simulated random mutations in any genome. We consider reference sequence (*Wuhan-Hu-1*) and mutation rate (per base) (Table 4) and use *ARGS mode* as defined in [60] to generate simulated sequences.

Table 3: Quantification of non-synonymous amino acid substitutions observed in different functional domains of S and N protein.

Protein	Domain	Substitution (freq)	# mutated position	Domain (%)	Overall (%)
S	RBD	Q314K(1), Q314L(1), Q314R(1), T315I(1), Q321L(1), T323I(2), P330S(1), T345S(1), A348S(1), A348T(1), N354K(1), V367F(4), C379F(1), V382E(1), V382L(1), P384L(1), T393P(1), R403K(1), R408I(1), L441I(1), R457K(1), E471Q(1), G476S(2), S477N(1), V483A(2), V483F(1), G485R(2), S494P(1), N501Y(1), H519Q(2), A520S(2), A522S(1), A522V(1), K529E(1)	28	12.55	10.72
	HR1	L922F(1), A924V(1), S929I(1), A930V(1), I931V(1), D936Y(1), S939F(2), S939Y(1), S940F(1), L981F(1)	9	12.85	3.44
	HR2	D1163G(1), D1168H(1), V1176F(1), K1181R(1), N1187K(1), N1187Y(1), K1191N(2), N1192T(1), E1195Q(1), Q1201K(1), L1203F(1), K1205N(1)	11	22.0	4.21
	FP	Y789D(1), T791I(5), K795Q(1), F797C(1)	4	22.22	1.53
	TM	G1219C(1), G1219V(1), V1228L(2), V1230L(1), M1237I(1), M1237T(1)	4	16.52	1.53
N	NTD	P46S(1), G60R(1), E62V(2), D63N(1), P67T(1), P67S(1), Q70H(1), S79T(1), D81Y(1), Q83R(1), R89I(1), A90S(1), R92S(1), R95L(1), G97S(1), S105N(1), A119V(2), A119S(1), G120R(1), P122L(1), A125T(1), D128Y(1), D128H(1), A134V(1), T135I(1), L139F(2), N140T(1), P142S(1), D144Y(3), D144H(2), H145Y(1), I146F(1), P151L(1), P151S(1), A152S(3), N154Y(1), A155V(1), A156S(3), I157T(1), Q163K(1), Q163R(1), T165I(1), T166I(1), L167F(1), P168Q(1), K169R(1)	40	29.6	23.95
	CTD	T247I(1), T247A(1), K249R(1), S250F(1), A252S(1), S255F(1), S255A(1), Q260L(1), Q260E(1), V270L(2), T271I(2), T282I(2), G284E(1), Q289H(1), Q289L(1), I292T(2), Q294L(1), D297Y(1), Y298H(1), H300Y(1), W301C(1), P302S(1), P309L(1), A311S(1), R319L(1), I320V(1), G321D(1), M322V(1), M322I(1), T325I(1), T325R(1), P326L(1), P326S(1), S327L(2), T329M(1), W330L(1), T334I(2), I337F(1), D340N(1), D340G(1), K342N(1), P344S(1), D348Y(4), D348H(1), K361I(1), T362I(2)	37	31.89	22.15

268 The mutation rate is the number of mutations per genetic unit at (gene, base) per unit
269 time (year, million years, or generation) [63]. We calculate mutation rate (μ) based on number
270 of mutations and distinct variants for each structural protein, which is calculated as follows:³

$$\mu = \frac{m}{t}.$$

271 where, m is the total number of mutations in k number of variants each of length l . In case of
272 per base and per gene mutation rate, $t = k \times l$, and $t = k$, respectively. The per base mutation
273 rate is relatively high for E protein followed by M , N , S , whereas mutation rate per gene is
274 high for S and N genes (Table 4).

Table 4: The mutation rate (per base and per gene) in four SARS-CoV-2 structural proteins. For calculating mutation rate, we considered mutation (non-synonymous substitutions) observed in all the variants of respective protein.

Gene	# variant	# mutation	Length (nucleotide)	Mutation rate (per base)	Mutation rate (per gene)
E	23	23	228	0.004386	1
M	50	50	669	0.001495	1
N	254	367	1260	0.001147	1.444882
S	354	691	3822	0.000510	1.951977

275 A total of five set of distinct simulated sequences (with non-synonymous mutations) are
276 generated. Each set is consisting of equal number of sequences as we have real and distinct
277 mutated sequences (or variant) for each structural protein of SARS-CoV-2 (Table 4).

278 We compare two sets by the Jaccard index, also known as the Jaccard similarity coefficient [64]. It is used to calculate similarity and diversity of sample sets. Given two sets of
279 real and simulated mutations/substitutions, R_m and S_m , respectively, it can be calculated as
280 follows.
281

$$J(R_m, S_m) = \frac{|R_m \cap S_m|}{|R_m \cup S_m|} = \frac{|R_m \cap S_m|}{|R_m| + |S_m| - |R_m \cap S_m|}. \quad (1)$$

³<http://www.biology.arizona.edu/evolution/working/act/mutation/population.html>

282 The value of $J(R_m, S_m)$ lies between 0 and 1, i.e. $0 \leq J(R_m, S_m) \leq 1$. The higher value of
 283 $J(R_m, S_m)$ indicates more similarities between the sample sets.

284 We report in Figure 7 the similarity scores for each protein. It can be observed that the
 285 Jaccard similarity for Nucleocapsid (N) and Spike (S) proteins substitutions is approximately
 286 0.6 and 0.5, respectively. However, Envelope (E) and Membrane (M) proteins show low simi-
 287 larity. The low similarity score further reflects that the mutations are non-uniform (as ARGS
 288 mode assumes uniform distribution) i.e. probability of mutations is not same in all positions.




Figure 7: Comparison of real and simulated substitutions. The Jaccard similarity score are shown for six set of compared simulated substitutions ($sim1, sim2, \dots, sim5$ and $sim1-5$) with the real substitution set.

289 4. Conclusion

290 In this work, we performed a sequence analysis on the structural proteins of SARS-CoV-
 291 2, reported from different parts of the world. All the unique sequences are grouped, and
 292 the variations are analyzed based on *Wuhan-Hu-1* SARS-CoV-2 sequence (as reference). We
 293 highlighted various commonly and rarely occurring amino acids substitution in four structural
 294 proteins. We reported location-wise amino acid substitution patterns in the structural proteins.
 295 The change in biochemical groupings as a result of substitutions are also reported for the
 296 candidate variants. We even highlighted the above variations specific to any particular country.

297 Although we observed much more unique variants in S protein than N protein, in terms
 298 of substitutions changes, N protein is much vulnerable as it shows the substitution in 40%
 299 positions. The majority of substitutions type for all four proteins are observed distinct, and
 300 they occur mostly in a particular location. The substitution type $A > V$ is very common for S,
 301 N, and M protein. We have highlighted few dominant substitutions that are co-occurred with
 302 several substitutions, particularly in S and N proteins. We further noted that the majority
 303 of the substitutions lead chemical group change from Aromatic and Aliphatic, Aliphatic and
 304 Hydroxyl-containing, and from Hydrophilic to Hydrophobic. A few substitutions in functional
 305 domains of S and N proteins are also highlighted found to be deleterious.

306 The overall study summarizes diversity amongst viruses sequenced early in the pandemic.
 307 We believe that the current findings will help better understand the disease pathogenesis of
 308 COVID-19 followed by suitable and relatively stable small molecule identification that may
 309 bind susceptible structural proteins like Spike (S) protein that is frequently changing.

310 Author contributions

311 J.K.D. and S.R. conceived and designed the research. J.K.D. collected, performed and
312 analyzed the data. J.K.D. wrote the original manuscript. S.R. reviewed and edited. All
313 authors read and approved the final manuscript.

314 Conflict of interest statement

315 The authors declare no conflict of interest.

316 Data availability statement

317 All the relevant data are presented withing the supplementary files.

318 References

- 319 [1] S. Herlitze, M. Koenen, A general and rapid mutagenesis method using polymerase chain
320 reaction, *Gene* 91 (1990) 143–147.
- 321 [2] M. C. Zambon, The pathogenesis of influenza in humans, *Reviews in medical virology* 11
322 (2001) 227–241.
- 323 [3] P. J. Walker, J. A. Cowley, Viral genetic variation: implications for disease diagnosis and
324 detection of shrimp pathogens, *FAO fisheries. Technical paper* (2000) 54–9.
- 325 [4] J. B. Watney, P. K. Agarwal, S. Hammes-Schiffer, Effect of mutation on enzyme motion in
326 dihydrofolate reductase, *Journal of the American Chemical Society* 125 (2003) 3745–3750.
- 327 [5] L.-L. Xue, Y.-H. Wang, Y. Xie, P. Yao, W.-H. Wang, W. Qian, Z.-X. Huang, J. Wu, Z.-X.
328 Xia, Effect of mutation at valine 61 on the three-dimensional structure, stability, and
329 redox potential of cytochrome b 5, *Biochemistry* 38 (1999) 11961–11972.
- 330 [6] A. E. Eriksson, W. A. Baase, X.-J. Zhang, D. W. Heinz, M. Blaber, E. P. Baldwin, B. W.
331 Matthews, Response of a protein structure to cavity-creating mutations and its relation
332 to the hydrophobic effect, *Science* 255 (1992) 178–183.
- 333 [7] E. Cota, S. J. Hamill, S. B. Fowler, J. Clarke, Two proteins with the same structure
334 respond very differently to mutation: the role of plasticity in protein stability, *Journal of*
335 *molecular biology* 302 (2000) 713–725.
- 336 [8] I. Adzhubei, D. M. Jordan, S. R. Sunyaev, Predicting functional effect of human missense
337 mutations using polyphen-2, *Current protocols in human genetics* 76 (2013) 7–20.
- 338 [9] Y. Sergeev, N. Smaoui, R. Sui, D. Stiles, N. Gordiyenko, N. Strunnikova, I. Macdon-
339 ald, The functional effect of pathogenic mutations in rab escort protein 1, *Mutation*
340 *Research/Fundamental and Molecular Mechanisms of Mutagenesis* 665 (2009) 44–50.
- 341 [10] J. D. Ramírez, M. Muñoz, C. Hernández, C. Florez, S. Gomez, A. Rico, L. Pardo, E. C.
342 Barros, A. E. Paniz-Mondolfi, Genetic diversity among sars-cov2 strains in south america
343 may impact performance of molecular detection, *Pathogens* 9 (2020) 580.
- 344 [11] V. D. Menachery, K. Debbink, R. S. Baric, Coronavirus non-structural protein 16: evasion,
345 attenuation, and possible treatments, *Virus research* 194 (2014) 191–199.

- 346 [12] L. R. Lopes, G. de Mattos Cardillo, P. B. Paiva, Molecular evolution and phylogenetic
347 analysis of sars-cov-2 and hosts ace2 protein suggest malayan pangolin as intermediary
348 host, *Brazilian Journal of Microbiology* (2020) 1–7.
- 349 [13] M. Uddin, F. Mustafa, T. A. Rizvi, T. Loney, H. A. Suwaidi, A. H. H. Al-Marzouqi,
350 A. K. Eldin, N. Alsabeeha, T. E. Adrian, C. Stefanini, et al., Sars-cov-2/covid-19: Viral
351 genomics, epidemiology, vaccines, and therapeutic interventions, *Viruses* 12 (2020) 526.
- 352 [14] X. Li, Y. Song, G. Wong, J. Cui, Bat origin of a new human coronavirus: there and back
353 again, *Science China Life Sciences* 63 (2020) 461–462.
- 354 [15] A. Chaudhuri, Comparative analysis of non structural protein 1 of sars-cov2 with sars-cov1
355 and mers-cov: An in silico study, *bioRxiv* (2020).
- 356 [16] A. Joshi, S. Paul, Phylogenetic analysis of the novel coronavirus reveals important variants
357 in indian strains, *BioRxiv* (2020).
- 358 [17] R. Sardar, D. Satish, S. Birla, D. Gupta, Comparative analyses of sar-cov2 genomes
359 from different geographical locations and other coronavirus family genomes reveals unique
360 features potentially consequential to host-virus interaction and pathogenesis, *bioRxiv*
361 (2020).
- 362 [18] T.-J. Chang, D.-M. Yang, M.-L. Wang, K.-H. Liang, P.-H. Tsai, S.-H. Chiou, T.-H. Lin,
363 C.-T. Wang, Genomic analysis and comparative multiple sequences of sars-cov2, *Journal*
364 *of the Chinese Medical Association* 83 (2020) 537–543.
- 365 [19] Y. Ruan, C. L. Wei, A. E. Ling, V. B. Vega, H. Thoreau, S. Y. S. Thoe, J.-M. Chia, P. Ng,
366 K. P. Chiu, L. Lim, et al., Comparative full-length genome sequence analysis of 14 sars
367 coronavirus isolates and common mutations associated with putative origins of infection,
368 *The Lancet* 361 (2003) 1779–1785.
- 369 [20] S. Perlman, J. Netland, Coronaviruses post-sars: update on replication and pathogenesis,
370 *Nature reviews microbiology* 7 (2009) 439–450.
- 371 [21] W. Song, M. Gui, X. Wang, Y. Xiang, Cryo-em structure of the sars coronavirus spike gly-
372 coprotein in complex with its host cell receptor ace2, *PLoS pathogens* 14 (2018) e1007236.
- 373 [22] J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, Q. Zhang, X. Shi, Q. Wang, L. Zhang, et al.,
374 Structure of the sars-cov-2 spike receptor-binding domain bound to the ace2 receptor,
375 *Nature* 581 (2020) 215–220.
- 376 [23] S. Xia, L. Yan, W. Xu, A. S. Agrawal, A. Algaissi, C.-T. K. Tseng, Q. Wang, L. Du,
377 W. Tan, I. A. Wilson, et al., A pan-coronavirus fusion inhibitor targeting the hr1 domain
378 of human coronavirus spike, *Science advances* 5 (2019) eaav4580.
- 379 [24] R. Hulswit, C. De Haan, B.-J. Bosch, Coronavirus spike protein and tropism changes, in:
380 *Advances in virus research*, volume 96, Elsevier, 2016, pp. 29–57.
- 381 [25] M. Surjit, B. Liu, P. Kumar, V. T. Chow, S. K. Lal, The nucleocapsid protein of the sars
382 coronavirus is capable of self-association through a c-terminal 209 amino acid interaction
383 domain, *Biochemical and biophysical research communications* 317 (2004) 1030–1036.
- 384 [26] Q. Huang, L. Yu, A. M. Petros, A. Gunasekera, Z. Liu, N. Xu, P. Hajduk, J. Mack, S. W.
385 Fesik, E. T. Olejniczak, Structure of the n-terminal rna-binding domain of the sars cov
386 nucleocapsid protein, *Biochemistry* 43 (2004) 6059–6063.

- 387 [27] X. Yan, Q. Hao, Y. Mu, K. A. Timani, L. Ye, Y. Zhu, J. Wu, Nucleocapsid protein
388 of sars-cov activates the expression of cyclooxygenase-2 by binding directly to regulatory
389 elements for nuclear factor-kappa b and ccaat/enhancer binding protein, *The international*
390 *journal of biochemistry & cell biology* 38 (2006) 1417–1428.
- 391 [28] Y. Hu, J. Wen, L. Tang, H. Zhang, X. Zhang, Y. Li, J. Wang, Y. Han, G. Li, J. Shi, et al.,
392 The m protein of sars-cov: basic structural and immunological properties, *Genomics,*
393 *proteomics & bioinformatics* 1 (2003) 118–130.
- 394 [29] S. Xia, M. Liu, C. Wang, W. Xu, Q. Lan, S. Feng, F. Qi, L. Bao, L. Du, S. Liu, et al., In-
395 hibition of sars-cov-2 (previously 2019-ncov) infection by a highly potent pan-coronavirus
396 fusion inhibitor targeting its spike protein that harbors a high capacity to mediate mem-
397 brane fusion, *Cell research* 30 (2020) 343–355.
- 398 [30] A. Naskalska, A. Dabrowska, A. Szczepanski, A. Milewska, K. P. Jasik, K. Pyrc, Membrane
399 protein of human coronavirus nl63 is responsible for interaction with the adhesion receptor,
400 *Journal of virology* 93 (2019) e00355–19.
- 401 [31] M.-S. Chang, Y.-T. Lu, S.-T. Ho, C.-C. Wu, T.-Y. Wei, C.-J. Chen, Y.-T. Hsu, P.-C. Chu,
402 C.-H. Chen, J.-M. Chu, et al., Antibody detection of sars-cov spike and nucleocapsid
403 protein, *Biochemical and biophysical research communications* 314 (2004) 931–936.
- 404 [32] A. B. Gussow, N. Auslander, G. Faure, Y. I. Wolf, F. Zhang, E. V. Koonin, Genomic
405 determinants of pathogenicity in sars-cov-2 and other human coronaviruses, *Proceedings*
406 *of the National Academy of Sciences* (2020).
- 407 [33] M. Bianchi, D. Benvenuto, M. Giovanetti, S. Angeletti, M. Ciccozzi, S. Pascarella, Sars-
408 cov-2 envelope and membrane proteins: Structural differences linked to virus characteris-
409 tics?, *BioMed Research International* 2020 (2020).
- 410 [34] R. E. Berry, M. N. Shokhirev, A. Y. Ho, F. Yang, T. K. Shokhireva, H. Zhang, A. Weichsel,
411 W. R. Montfort, F. A. Walker, Effect of mutation of carboxyl side-chain amino acids near
412 the heme on the midpoint potentials and ligand binding constants of nitrophorin 2 and its
413 no, histamine, and imidazole complexes, *Journal of the American Chemical Society* 131
414 (2009) 2313–2327.
- 415 [35] C. N. Pace, Contribution of the hydrophobic effect to globular protein stability, *Journal*
416 *of molecular biology* 226 (1992) 29–35.
- 417 [36] M. J. Betts, R. B. Russell, Amino acid properties and consequences of substitutions,
418 *Bioinformatics for geneticists* 317 (2003) 289.
- 419 [37] A. Haimeur, G. Conseil, R. G. Deeley, S. P. Cole, Mutations of charged amino acids in or
420 near the transmembrane helices of the second membrane spanning domain differentially
421 affect the substrate specificity and transport activity of the multidrug resistance protein
422 mrp1 (abcc1), *Molecular pharmacology* 65 (2004) 1375–1385.
- 423 [38] B. E. Bowler, K. May, T. Zaragoza, P. York, A. Dong, W. S. Caughey, Destabilizing effects
424 of replacing a surface lysine of cytochrome c with aromatic amino acids: implications for
425 the denatured state, *Biochemistry* 32 (1993) 183–190.
- 426 [39] P. Basak, S. Maitra-Majee, J. K. Das, A. Mukherjee, S. Ghosh Dastidar, P. Pal Choudhury,
427 A. Lahiri Majumder, An evolutionary analysis identifies a conserved pentapeptide stretch
428 containing the two essential lysine residues for rice l-myo-inositol 1-phosphate synthase
429 catalytic activity, *PloS one* 12 (2017) e0185351.

- 430 [40] J. Ogawa, W. Zhu, N. Tonnu, O. Singer, T. Hunter, A. L. Ryan, G. M. Pao, The d614g
431 mutation in the sars-cov2 spike protein increases infectivity in an ace2 receptor dependent
432 manner, *bioRxiv* (2020).
- 433 [41] F. Begum, D. Mukherjee, S. Das, D. Thagriki, P. P. Tripathi, A. K. Banerjee, U. Ray,
434 Specific mutations in sars-cov2 rna dependent rna polymerase and helicase alter protein
435 structure, dynamics and thus function: Effect on viral rna replication, *bioRxiv* (2020).
- 436 [42] C. Shu, X. Huang, J. Brosius, C. Deng, Exploring potential super infection in sars-cov2
437 by genome-wide analysis and receptor–ligand docking (2020).
- 438 [43] S. Saurabh, S. S. Purohit, A modified ace2 peptide mimic to block sars-cov2 entry, *bioRxiv*
439 (2020).
- 440 [44] M. Tiwari, D. Mishra, Investigating the genomic landscape of novel coronavirus (2019-
441 ncov) to identify non-synonymous mutations for use in diagnosis and drug design, *Journal*
442 *of Clinical Virology* (2020) 104441.
- 443 [45] N. Chitranshi, V. K. Gupta, R. Rajput, A. Godinez, K. Pushpitha, T. Sheng, M. Mirzaei,
444 Y. You, D. Basavarajappa, V. Gupta, et al., Evolving geographic diversity in sars-cov2
445 and in silico analysis of replicating enzyme 3clpro targeting repurposed drug candidates
446 (2020).
- 447 [46] S. Kumar, G. Stecher, M. Li, C. Knyaz, K. Tamura, Mega x: molecular evolutionary
448 genetics analysis across computing platforms, *Molecular biology and evolution* 35 (2018)
449 1547–1549.
- 450 [47] E. P. Rocha, A. Danchin, An analysis of determinants of amino acids substitution rates
451 in bacterial proteins, *Molecular biology and evolution* 21 (2004) 108–116.
- 452 [48] P. C. Ng, S. Henikoff, Sift: Predicting amino acid changes that affect protein function,
453 *Nucleic acids research* 31 (2003) 3812–3814.
- 454 [49] E. A. Stone, A. Sidow, Physicochemical constraint violation by missense substitutions
455 mediates impairment of protein function and disease severity, *Genome research* 15 (2005)
456 978–986.
- 457 [50] J. K. Das, P. Das, K. K. Ray, P. P. Choudhury, S. S. Jana, Mathematical characterization
458 of protein sequences using patterns as chemical group combinations of amino acids, *PloS*
459 *one* 11 (2016) e0167651.
- 460 [51] C. Pommié, S. Levadoux, R. Sabatier, G. Lefranc, M.-P. Lefranc, Imgt standardized
461 criteria for statistical analysis of immunoglobulin v-region amino acid properties, *Journal*
462 *of Molecular Recognition* 17 (2004) 17–32.
- 463 [52] M. Gui, W. Song, H. Zhou, J. Xu, S. Chen, Y. Xiang, X. Wang, Cryo-electron microscopy
464 structures of the sars-cov spike glycoprotein reveal a prerequisite conformational state for
465 receptor binding, *Cell research* 27 (2017) 119–129.
- 466 [53] A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, D. Veessler, Structure,
467 function, and antigenicity of the sars-cov-2 spike glycoprotein, *Cell* (2020).
- 468 [54] J. Cui, F. Li, Z.-L. Shi, Origin and evolution of pathogenic coronaviruses, *Nature Reviews*
469 *Microbiology* 17 (2019) 181–192.

- 470 [55] Q. Wang, Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, C. Qiao, Y. Hu, K.-Y.
471 Yuen, et al., Structural and functional basis of sars-cov-2 entry by using human ace2, *Cell*
472 (2020).
- 473 [56] X. Ou, W. Zheng, Y. Shan, Z. Mu, S. R. Dominguez, K. V. Holmes, Z. Qian, Identification
474 of the fusion peptide-containing region in betacoronavirus spike glycoproteins, *Journal of*
475 *virology* 90 (2016) 5586–5600.
- 476 [57] Y. Huang, C. Yang, X.-f. Xu, W. Xu, S.-w. Liu, Structural and functional properties of
477 sars-cov-2 spike protein: potential antivirus drug development for covid-19, *Acta Phar-*
478 *macologica Sinica* (2020) 1–9.
- 479 [58] W. Zeng, G. Liu, H. Ma, D. Zhao, Y. Yang, M. Liu, A. Mohammed, C. Zhao, Y. Yang,
480 J. Xie, et al., Biochemical characterization of sars-cov-2 nucleocapsid protein, *Biochemical*
481 *and biophysical research communications* (2020).
- 482 [59] Y. Choi, A. P. Chan, Provean web server: a tool to predict the functional effect of amino
483 acid substitutions and indels, *Bioinformatics* 31 (2015) 2745–2747.
- 484 [60] M. Kühnl, B. Stich, D. Ries, Mutation-simulator: fine-grained simulation of random mu-
485 tations in any genome, *Bioinformatics* (2020).
- 486 [61] C.-Y. Chen, C.-k. Chang, Y.-W. Chang, S.-C. Sue, H.-I. Bai, L. Riang, C.-D. Hsiao, T.-h.
487 Huang, Structure of the sars coronavirus nucleocapsid protein rna-binding dimerization
488 domain suggests a mechanism for helical packaging of viral rna, *Journal of molecular*
489 *biology* 368 (2007) 1075–1086.
- 490 [62] S. M. Cascarina, E. D. Ross, A proposed role for the sars-cov-2 nucleocapsid protein in
491 the formation and regulation of biomolecular condensates, *The FASEB Journal* (2020).
- 492 [63] J. F. Crow, The high spontaneous mutation rate: is it a health risk?, *Proceedings of the*
493 *National Academy of Sciences* 94 (1997) 8380–8386.
- 494 [64] P. Jaccard, The distribution of the flora in the alpine zone. 1, *New phytologist* 11 (1912)
495 37–50.